Kiniksa Pharmaceuticals International plc (KNSA) is riding high on the success of its flagship product Arcalyst. With Arcalyst posting a near 90% revenue surge in the second quarter of 2024, the company has once again raised its revenue forecast for the year.
Arcalyst is the first and only FDA-approved therapy for recurrent pericarditis, a painful and debilitating auto-inflammatory cardiovascular disease. The drug was licensed from Regeneron in 2017.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.